Patients with clinically metabolically healthy obesity are not necessarily healthy subclinically: further support for bariatric surgery in patients without metabolic disease?

• Main Authors: Haskins, Ivy N., Chang, Julietta, Nor Hanipah, Zubaidah, Singh, Tavankit, Mehta, Neal, McCullough, Arthur J., Brethauer, Stacy A., Schauer, Philip R., Aminian, Ali
• Format: Article
• Language: English
• Published: Elsevier 2018
• Online Access: http://psasir.upm.edu.my/id/eprint/75212/1/Patients%20with%20clinically%20metabolically%20healthy%20obesity%20are%20not%20necessarily%20healthy%20subclinically.pdf; http://psasir.upm.edu.my/id/eprint/75212/; https://www.sciencedirect.com/science/article/abs/pii/S155072891731081X?via%3Dihub; https://doi.org/10.1016/j.soard.2017.11.032
• Institution: Universiti Putra Malaysia

Background: Nonalcoholic fatty liver disease (NAFLD) increases the risk of liver cirrhosis and hepatocellular carcinoma and is also strongly correlated with extrahepatic diseases, including cardiovascular disease and type 2 diabetes. This risk of NAFLD among obese individuals who are otherwise metabolically healthy is not well characterized. Objectives: To determine the prevalence and characteristics of NAFLD in individuals with metabolically healthy obesity. Setting: A tertiary, academic, referral hospital. Methods: All patients who underwent bariatric surgery with intraoperative liver biopsy from 2008 to 2015 were identified. Patients with preoperative hypertension, dyslipidemia, or prediabetes/diabetes were excluded to identify a cohort of metabolically healthy obesity patients. Liver biopsy reports were reviewed to determine the prevalence of NAFLD. Results: A total of 270 patients (7.0% of the total bariatric surgery patients) met the strict inclusion criteria for metabolically healthy obesity. The average age was 38 ± 10 years and the average body mass index was 47 ± 7 kg/m2. Abnormal alanine aminotransferase (>45 U/L) and asparate aminotransferase levels (>40 U/L) were observed in 28 (10.4%) and 18 (6.7%) patients, respectively. A total of 96 (35.5%) patients had NAFLD with NALFD Activity Scores 0 to 2 (n = 61), 3 to 4 (n = 25), and 5 to 8 (n = 10). A total of 62 (23%) patients had lobular inflammation, 23 (8.5%) had hepatocyte ballooning, 22 (8.2%) had steatohepatitis, and 12 (4.4%) had liver fibrosis. Conclusion: Even with the use of strict criteria to eliminate all patients with any metabolic problems, a significant proportion of metabolically healthy patients had unsuspected NAFLD. The need and clinical utility of routine screening of obese patients for fatty liver disease and the role of bariatric surgery in the management of NAFLD warrants further investigation.